Background Astrocytic tumors are the most common primary central nervous system tumors. Glioma stem cells are thought to be responsible for the initiation, the invasion, the radioresistance, and the repopulation of astrocytomas. Nestin and CD133 are markers of neural and cancer stem cells.
Introduction
Astrocytic tumors are the most common primary central nervous system (CNS) tumors. The diffuse type of these tumors have an inherit tendency for progression and recurrence (Burger and Scheithauer, 2007) . Routine histopathological examination and grading do not always identify the subset of these tumors, especially when the tumor sample is small or inadequate (Mahzouni et al., 2010) . Numerous studies indicate that the growth of gliomas is initiated and driven by a subpopulation of cancer cells with stem cell-like characteristics, including the self-renewal capacity and the ability to differentiate. These cells were called glioma stem cells (GSCs). GSCs are thought to be responsible for the initiation, the invasion, the radioresistance, and the repopulation of astrocytomas (Sanai et al., 2005) .
Nestin is a class VI intermediate filament protein expressed in undifferentiated CNS neural cells and radial glia during development, with downregulation after passing to the postmitotic phase (Lendahl et al., 1990) . This protein is a neural stem cell (NSC) marker and is required for the survival and the self-renewal of NSCs. It may be involved in the organization of the cytoskeleton, cell signaling and metabolism, and organogenesis (Park et al., 2010) . Nestin is upregulated in many tumor types, especially those originating from stem/progenitor cells. These tumors include CNS tumors (neurocytomas, gangliogliomas, ependymomas, pilocytic astrocytomas, malignant gliomas including glioblastoma, CNS primitive neuroectodermal tumors, medulloblastomas, and medulloepitheliomas) (Dahlstrand et al., 1992) and non-CNS tumors (rhabdomyosarcomas, gastrointestinal stromal tumors, and melanomas) (Ishiwata et al., 2011a) . Nestin was also correlated to the proliferative activity, the migration capacity, and the invasiveness of several cell lines derived from astrocytic tumors (Ishiwata et al., 2011b) . CD133 (also known as promonin-1 or AC133) is a pentaspan transmembrane glycoprotein of uncertain function. It is a marker of neuroepithelial stem cells and of a unique population of cancer cells believed to be 'cancer stem cells' (Fargeas et al., 2007) . CD133 is expressed in GSCs and hence is expressed in a variety of human tumors including glioblastoma in which CD133 is related to angiogenesis, radiochemoresistance, and tumor aggressiveness. Growing data demonstrate that CD133 expression is related to an adverse prognosis in glioblastoma (Zeppernick et al., 2008) . However, there is considerable controversy about its prognostic significance in astrocytomas (Dahlrot et al., 2014) .
This study was carried out to evaluate the immunohistochemical expression of nestin and CD133 in different types and grades of astrocytomas in Egyptian patients in relation to the available clinicopathological data (age, size, grade, and survival).
Materials and methods
The study comprised 72 formalin-fixed paraffin-embedded tissue blocks from cases of astrocytoma of different grades (grades I to IV), collected from the archives of the pathology department, Tanta University Hospital, and private laboratories, with their clinicopathologic data and the available follow-up data. The size of the tumors was assessed from the imaging studies (computed tomography and/or MRI). The greatest dimension of the tumor was taken as a measure of the tumor size.
The blocks were stained immunohistochemically using the Avidin-Biotin method for nestin (mouse monoclonal antibody; Clone: Nbla00170; Cat # N2060-05E; Lab Vision, Fremont, California, USA) and CD133 (Rabbit Polyclonal antibody Clone: MSTP061, Cat # 137634; Lab Vision). For immunostaining, 4 mm sections were deparaffinized in xylene, and then rehydrated in descending concentration of ethanol. The blockage of endogenous peroxidases (by incubation in 0.3% H 2 O 2 for 30 min) was followed by microwave treatment (15 min in 10 mmol/l sodium citrate buffer pH 6.0) for antigen retrieval. Slides were then incubated with the primary antibodies mentioned earlier overnight in a humid chamber at 41C. Specific binding was detected using the LSAB 2 kit (Dako, Carpinteria, California, USA) according to the manufacturer's instructions. Sections were washed with PBS after each step. PBS was used instead of the primary antibody as the negative control.
Membranous and/or cytoplasmic staining of both markers were considered positive. The expression of each marker was evaluated blindly by three pathologists (M.S., R.W. and H.S.) separately in 10 representative high-power fields and scored into 0, 1, 2, and 3 according to three cutoff values of 0% (no staining), 30%, and 60%. In case of different score evaluation, an agreement was reached by a consensus meeting on a multiheaded microscope. Scores of 0 (no staining detected) and 1 (staining in <30% of the tumor cells) were considered as low expression and scores of 2 (staining in 30-60% of the tumor cells) and 3 (staining in more than 60% of the tumor cells) were considered as high expression (Zhang et al., 2008) . The expression was then correlated to the clinicopathologic (age, sex, size, and grade) and follow-up data.
Results

Clinicopathological data
The study included 72 cases of astrocytic tumors, including 24 cases of low-grade astrocytomas (grades I and II) [12 male and 12 female patients with an age range of 1-60 years; mean age 29.9( ± 16.6) years] and 48 cases of the high-grade types (grades III and IV) [24 male and 24 female patients with an age range of 16-75 years; mean 49.9( ± 14.3) years]. Follow-up data were available for 46 patients, of whom 30 patients were dead of disease and 16 were living without evidence of recurrences. The follow-up period ranged from 1 to 70 months, with a median follow-up of 35.5 months.
Low-grade cases comprised 13 cases of pilocytic astrocytoma, one case of subependymal giant-cell astrocytoma, two cases of pilomyxoid astrocytoma, one case of pleomorphic xanthoastrocytoma, and seven cases of diffuse astrocytoma. The size range of low-grade types was 3-8 cm, with mean size 4.9( ± 1.42) cm. The followup ranged from 1 to 70 months, with a mean progressionfree survival of 19.39( ± 17.44) months.
High-grade cases comprised six cases of anaplastic astrocytoma and 42 cases of glioblastoma (comprised one case of a giant-cell variant, two cases of a small-cell variant, and one case of glioblastoma with oligodendroglial differentiation). Glioblastoma cases included two secondary cases and one recurrent case. The size range for high-grade types was 3.5-8.5 cm, with a mean size of 5.2 ( ± 1.27) cm. The follow-up period ranged was from 1 to 30 months, with a mean progression-free survival of 6.25( ± 7.48) months. The progression-free survival of low-grade astrocytomas was significantly longer than that of high-grade types (P = 0.002).
Nestin immunohistochemistry
Nestin was positive in 69/72 (95.8%) cases. Nestin immunoreactivity was cytoplasmic in all positive cases. In addition to cytoplasmic positivity, nestin showed nuclear positivity (focal to diffuse) in positive low-grade astrocytomas ( Fig. 1 ) and gemistocytic astrocytomas ( Fig. 2) and membranous positivity in 6/42 (14.3%) cases of glioblastomas ( Fig. 3 ). Nestin positivity was found in the small cells of lowgrade gemistocytic astrocytomas, and both the small and the large cells of high-grade gemistocytic astrocytomas. Glioblastoma with oligodendroglial differentiation was completely negative for nestin.
Nestin showed higher expression in high-grade astrocytomas [high expression in 19/24 (79%) low-grade astrocytomas (grades I and II) vs. 47/48 (98%) highgrade astrocytomas (grades III and IV); P = 0.014] (Table 1) . Nestin also showed significant positive correlation with the tumor grade (r = 0.18, P = 0.001). No significant relation was found between nestin expression and the age, the sex, the tumor size, or the tumor location.
CD 133 immunohistochemistry CD133 immunoreactivity was cytoplasmic in all positive cases (without any detectable nuclear positivity). Positivity was detected in 51/72 (70.8%) cases. CD133 showed a higher expression in high-grade astrocytomas [high expression in 1/24 (4.2%) of low-grade astrocytomas (Fig. 4) vs. 34/48 (71%) high-grade astrocytomas (Figs 5 and 6; P = 0.001)] ( Table 2) . CD133 showed significant correlation with the tumor grade (r = 0.2, P = 0.001) and the tumor size (r = 0.34, P = 0.01). No significant relation was found between CD133 expression and the age, the sex, or the tumor location. A strong positive relation was found between nestin and CD133 expression (r = 0.64, P = 0.001).
The relation of nestin and CD133 to survival data
The relation between nestin and CD133 expression and the survival data is represented in Table 3 . Nestin expression was significantly higher in tumors from patients who succumbed to the disease than in tumors from patients living free of disease (P = 0.042). In contrast, CD133 expression did not show a significant difference between these two groups of patients (P = 0.931). Singh et al. (2003) were the first to identify a cellular subpopulation showing an unlimited proliferative potential and sharing many properties with NSCs in malignant brain tumors. This stem cell-like population displayed an even higher self-renewal and proliferation ability compared with NSCs. They expressed NSC markers, such as nestin and CD133 (Singh et al., 2004) . These tumor stem cells, termed GSCs in glial tumors, are resistant to radiotherapy and chemotherapy and have been proved to be the cause of the well-known failure of surgical treatment in malignant gliomas (Sanai et al., 2005) .
Discussion
Consequently, an increasing body of GSC research has been carried out.
Nestin, a class VI intermediate filament protein, is considered as a marker of GSCs. It has been detected in a variety of astrocytic tumors such as pilocytic astrocytoma and glioblastoma (Dahlstrand et al., 1992 ).
In the current study, nestin expression was detected in 95.8% of the astrocytic tumors, a result higher than that obtained by other studies, such as Mangiola et al. (2007) and Zhang et al. (2008) , who detected nestin expression in 85.58 and 84.7% of the astrocytoma cases, respectively (Mangiola et al., 2007; Zhang et al., 2008) . This may be attributed to the high incidence of glioblastoma cases in our study and the fact that glioblastoma has a higher nestin expression, as reported previously by Shih and Holland (2006) . In the present work, nestin expression in glioblastoma was 97.6%, a finding that approached that of Chinnaiyan et al. (2008) , who studied nestin in glioblastoma cases and detected nestin expression in 98% of the cases.
In the present work, nestin expression was detected more frequently in high-grade astrocytomas (97.9%) than in low-grade astrocytomas (91.7%), with significant direct correlation with the tumor grade. Nestin expression was also found to be higher in patients who succumbed to disease. This may throw light on the prognostic value of nestin in astrocytomas. Many studies agree with this prognostic value of nestin in astrocytomas (Maderna et al., 2007; Zhang et al., 2008) . Many studies also stated that nestin has an even stronger prognostic value than histological grading (Strojnik et al., 2007; Zhang et al., 2008; Dahlrot et al., 2014) .
In addition, studies testing nestin expression in low-grade astrocytomas have shown that nestin expression was associated with poor prognosis in these cases (Dahlstrand et al., 1992; Ehrmann et al., 2005; Maderna et al., Fig. 6 A glioblastoma (grade IV) showing strong cytoplasmic positivity for CD133 (original magnification, Â 400). 2007; Strojnik et al., 2007; Dahlrot et al., 2014; Dell'albani et al., 2014) . Hence, nestin expression may potentially serve as a biologic marker for high-risk low-grade astrocytomas, which could have a direct clinical application. The strong prognostic value of nestin and its relation with grading in astrocytomas stands for the biologic role of GSCs in astrocytoma, making the targeting of these cells a potentially promising therapeutic strategy.
Astrocytoma with prominent gemistocytic differentiation, the so-called gemistocytic astrocytoma, is known for its propensity for aggressive behavior and grade progression (Louis et al., 2007; Babu et al., 2013) . The rate of grade progression [from the low-grade variant (grade II) to the high-grade variants (grades III and IV)] is related to a population of cells with hyperchromatic nuclei and scanty cytoplasm (as opposed to the gemistocytic astrocytes with abundant eosinophilic cytoplasm) (Burger and Scheithauer, 2007) . This small cell population has a higher proliferative index than the larger gemistocytic cells and is thought to be the causative cell of progression of the gemistocytic astrocytoma grade II to high-grade types of anaplastic gemiostocytic astrocytoma grade III and glioblastoma grade IV (Burger and Scheithauer, 2007; Louis et al., 2007) . The observed nestin positivity in the smaller cell population in low-grade gemisotcytic astrocytoma in our study points toward the role of stem cells in the progression of this aggressive variant of astrocytomas, further substantiating the biologic role of GSCs in astrocytomas.
CD133 (Prominin), a cell surface neuroepithelial stem cell marker, was detected as cytoplasmic staining in 70.8% of our astrocytoma cases. The expression of CD133 in astrocytoma is subject to wide variability in the literature. Zhang et al. (2008) and Melguizo et al. (2012) reported CD133 expression of 77.6 and 96.2% in astrocytomas, respectively (Zhang et al., 2008; Melguizo et al., 2012) . This wide variability may be attributed to the different specificity and sensitivity of the different commercially available antibodies used in these studies. It was reported that different CD133 antibody clones identify different epitopes and even epitopes with different glycosylation status (Hermansen et al., 2011) .
CD 133 was reported to be related to many malignant characteristics in astrocytomas, including cell proliferation, angiogenesis, and invasiveness (Beier et al., 2007; Liu et al., 2013) . In the present study, CD 133 expression was higher in high-grade astrocytomas and significantly positively correlated to the tumor grade and the tumor size, among other different tested tumor parameters. These relations are in harmony with the reported high-proliferative and low-apoptotic indices of CD133-positive astrocytomas (Beier et al., 2007; Ding et al., 2013; Liu et al., 2013) .
Despite the above-mentioned reported aggressive biological characteristics imparted by CD133 positivity in astrocytomas, considerable controversy is found in the literature concerning its prognostic value in astrocytomas (especially high-grade astrocytomas and glioblastoma). In the present work, there was no statistically significant correlation between CD133 expression and patient survival. This result was in agreement with many studies (Christensen et al., 2008; Kim et al., 2011; Melguizo et al., 2012; Dahlrot et al., 2014) . In contrast, many studies claimed that CD 133 is a marker of bad prognosis in astrocytic tumors (especially the high-grade variety) (Ma et al., 2008; Pallini et al., 2008; Zeppernick et al., 2008; Zhang et al., 2008; Thon et al., 2010; Shin et al., 2013) . As these studies included all WHO grades as one group, it may be questioned whether the WHO grade or the CD133 contents of the tumor is the cause of the poor prognosis, because CD133 expression increases with grades in these studies.
Interestingly, Pallini et al. (2011) reported that the CD133-positive cell fraction increases in recurrent glioblastoma relative to the primary tumor (up to 20folds). Nevertheless, the increased CD133 positivity in recurrent glioblastomas has had a favorable prognostic impact. They found that the CD133-positive cellular fraction contains both stem cell and nonstem cell components. However, they hypothesized that the good prognostic effect is imparted by the CD133-positive nonstem cell component (Pallini et al., 2011) .
These complex data and controversies may be explained by the finding of a small fraction of CD133-negative cells with stem cell characteristics and CD133-positive cells without stem cell characteristics in astrocytomas by many groups of researchers (Beier et al., 2007; Joo et al., 2008; Wang et al., 2008; Chen et al., 2010) . These findings may compromise the specificity of CD133 as a stem cell marker in astrocytomas. However, its relation to the grade, proliferation, and other aggressive biological features in astrocytomas may be beneficial in many ways.
A strong positive correlation was found between nestin and CD133 in the present study. This may be anticipated as studies exploring the characteristics of CD133 + ve cells (especially in high-grade astrocytomas) pointed toward the high incidence of nestin positivity in CD133-positive cells (Beier et al., 2007; Zhang et al., 2008; Liu et al., 2013; Dahlrot et al., 2014) .
Nestin expression was higher in patients who succumbed to the disease, whereas CD133 did not show this difference. This result is partially in agreement with Dahlrot et al. (2014) , who found nestin to be valid as a prognostic marker in low-grade astrocytomas, yet not CD133 (Dahlrot et al., 2014) . However, Zhang et al. (2008) found both markers of good prognostic value and advocate combined testing for both, with the view that nestin/CD133 coexpression carries an ominous prognosis in high-grade astrocytomas (Zhang et al., 2008) .
Conclusion
Nestin and CD133 are markers of the aggressive behavior of astrocytomas in Egyptian patients. High nestin expression can be considered as an ominous prognostic factor in high-grade astrocytomas. The two markers may be used as an ancillary method for grading and/or directing the therapeutic decision, especially in small biopsy specimens. The high expression of these two cancer stem cell markers in aggressive astrocytomas Nestin and CD133 in astrocytomas Shareef et al. 51 supports the role of GSCs in the aggressiveness of astrocytomas.
